CovalAb S.A.R.L (CovalAb) is a privately held specialty pharmaceutical company. It is principally engaged in manufacturing and supplying polyclonal and monoclonal antibodies, and synthetic peptides. The company offers primary antibodies including, monoclonal and polyclonal addressing post translational modification reactions, cancer research, virology, neurosciences and various other associated fields. In addition, it also offers Secondary antibodies; functionalised microtiter plates; and also beads, columns, and kits. Further, the company offers a wide rage of custom antibody services, monoclonal antibodies production, ELISA kit development, antibody purification and labelling and peptide synthesis services. It also offering the antibodies for treating the cancer. CovalAb is headquartered in Villeurbanne, France.